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A B S T R A C T
Fenretinide (FEN) is a synthetic retinoid that inhibits obesity and insulin resistance in high-fat diet (HFD)-
fed mice and completely prevents 3T3-L1 pre-adipocyte differentiation. The aim of this study was to
determine the mechanism(s) of FEN action in 3T3-L1 adipocytes and in mice. We used the 3T3-L1 model
of adipogenesis, fully differentiated 3T3-L1 adipocytes and adipose tissue from HFD-induced obese mice
to investigate the mechanisms of FEN action. We measured expression of adipogenic and retinoid genes
by qPCR and activation of nutrient-signalling pathways by western blotting. Global lipid and metabolite
analysis was performed and speciﬁc ceramide lipid species measured by liquid chromatography-mass
spectrometry. We provide direct evidence that FEN inhibits 3T3-L1 adipogenesis via RA-receptor (RAR)-
dependent signaling. However, RARa antagonism did not prevent FEN-induced decreases in lipid levels
in mature 3T3-L1 adipocytes, suggesting an RAR-independent mechanism. Lipidomics analysis revealed
that FEN increased dihydroceramide lipid species 5- to 16-fold in adipocytes, indicating an inhibition of
the ﬁnal step of ceramide biosynthesis. A similar blockade in adipose tissue from FEN-treated obese mice
was associated with a complete normalisation of impaired mitochondrial b-oxidation and tricarboxylic
acid cycle ﬂux. The FEN catabolite, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-OXO), also decreased lipid
accumulation without affecting adipogenesis. FEN and 4-OXO (but not RA) treatment additionally led to
the activation of p38-MAPK, peIF2a and autophagy markers in adipocytes. Overall our data reveals FEN
utilises both RAR-dependent and -independent pathways to regulate adipocyte biology, both of which
may be required for FEN to prevent obesity and insulin resistance in vivo.
ã 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Retinol (vitamin A) and the retinoid metabolism pathway play
an important role in body mass regulation and adipocyte biology
[1–6]. Targeting retinoid homeostasis may therefore offer a* Corresponding author.
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0006-2952/ã 2015 The Authors. Published by Elsevier Inc. This is an open access artictherapeutic approach for obesity and type-2 diabetes. Vitamin A
is a lipid soluble molecule which undergoes multiple steps of
metabolism through a complex pathway of enzymes and transport
proteins [7]. All-trans-retinoic acid (RA), which is the most active
metabolite of retinol, has long been known to inhibit adipogenesis
through the prevention of C/EBPb mediated transcription [1,8],
More recently, RA has been shown to improve obesity and glucose
homeostasis in vivo [4]. However, with prolonged exposure,
naturally derived retinoid compounds such as RA and retinyl-
acetate can lead to liver toxicity, which restricts their potential use
as therapeutic agents [9].
Fenretinide (FEN), otherwise known as N-(4-hydroxyphenyl)
retinamide or 4-HPR, is a structural derivative of RA with reducedle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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clearance and thus decreased serum levels of the retinol transport
protein, serum retinol binding protein (gene name Rbp4) in both
humans and mice [12–16]. This decrease in circulating RBP4 levels
had been proposed to be the mechanism that FEN treatment led to
prevention of insulin resistance associated with high-fat diet (HFD)
induced obesity [15]. However, FEN has also been shown to reduce
obesity and hyperleptinaemia in mice lacking RBP4, implying that
the anti-obesity effects of FEN are most likely to be independent of
its ability to decrease circulating RBP4 levels [16].
Thus, the beneﬁcial effects of FEN appear to be through several
different mechanisms including alterations to retinoid homeosta-
sis in multiple tissues [6], increased hepatic lipid oxidation [17]
and inhibition of ceramide biosynthesis leading to an increase in
dihydroceramide in muscle and liver [18]. Studies in cancer cells
have found that both FEN and dihydroceramide treatment are
associated with the activation of cellular stress responses and
autophagy induction [19–21]. Autophagy plays a crucial role in
cellular homeostasis through the degradation and recycling of
organelles such as mitochondria or ER and the regulation of
intracellular lipid stores [22,23]. Since defective autophagy may
also underlie impaired insulin sensitivity in obesity and upregulat-
ing autophagy may be a useful strategy to combat insulin
resistance [24–26], it highlights the importance to further
characterise the biological effects of FEN.
In addition to the beneﬁcial effect of FEN in vivo, we recently
demonstrated that FEN (similarly to RA) is able to inhibit 3T3-
L1 adipocyte differentiation by blocking transcription of C/EBPa
and PPARg, master regulators that synergistically coordinate
adipogenesis and adipocyte biology and simultaneously increas-
ing retinoid gene expression [6]. Interestingly, rosiglitazone
(ROSI), a thiazolidinedione and PPARg agonist commonly used to
stimulate adipogenesis, suppressed gene expression of all the
retinoid metabolism markers examined in differentiating 3T3-
L1 cells [6]. FEN also decreased lipid accumulation in fully
differentiated 3T3-L1 adipocytes [6], but RA treatment did not
[27,28]. Thus, FEN and RA appear to have divergent biological
effects which may be due to unique activation of retinoic acid
receptor (RAR)-dependent and -independent pathways. Since, it
is unknown which pathway FEN requires for its biological effects
in adipocytes we aimed to determine the mechanism(s) of FEN
action in the 3T3-L1 model of pre-adipocyte differentiation and
fully differentiated adipocytes. In addition, we have translated
some of our new ﬁndings to adipose tissue of HFD-induced
obese mice.
2. Methods
2.1. Cell culture
3T3-L1 pre-adipocytes were maintained and differentiated for
8 days (or 16 days where stated) as previously described [6].
C3H10T1/2 cells were similarly treated however penicillin/
streptomycin was omitted from the media. DMSO was used as
vehicle control (VEH) and to dissolve all experimental compounds.
FEN (Cilag AG, Schaffhausen, Switzerland), RA (Sigma–Aldrich, UK)
and ROSI (Cayman Chemical, MI, USA) were used at 1 mM, 4-OXO
(Santa Cruz, TX, USA) at 0.5 mM and ER50891 (Tocris Bioscience,
Bristol, UK) at 10 mM and added at day 0 (or day 8 where indicated).
Cells were stained for neutral lipids with Oil Red O, images taken
and then the stain was eluted and quantiﬁed at 520 nm.
2.2. Lipolysis assay
Basal glycerol levels were measured in media collected at day
16 of differentiation from 3T3-L1 cultures. The Triglyceride Liquidassay (Sentinel Diagnostics #17628) was used following the
supplied protocol.
2.3. Gene expression and protein analysis
RNA isolation, cDNA synthesis and qPCR were performed at day
8 of differentiation (or as stated in the ﬁgure legends) as previously
described [6]. Control reactions for contaminating DNA were
performed routinely and relative expression calculated using the
Pfafﬂ method [29]. The geometric mean of three stable reference
genes (Nono, Ywhaz and Actb or as stated in the ﬁgure legend) were
obtained from ﬁve commonly used sequences and used for
normalisation. Primer sequences available on request, some of
which were obtained from PrimerBank [30].
SDS-PAGE was performed and transferred to nitrocellulose
membranes as described previously [31]. Antibodies against
p-eIF2a (#9721), eIF2 a (#5324S), p-p38 MAPK (#9211),
p38 MAPK (#8690S), Beclin1 (#3495), LC3B (#3868), p-Akt
Ser473 (#9271) were from Cell Signalling, SH-PTP2 (sc-280) and
Akt1/2/3 (sc-8312) from Santa Cruz. All antibodies were detected
with goat anti-rabbit HRP secondary antibody (#28177) from
Anaspec. Proteins were visualized using enhanced chemilumines-
cence (ECL) and quantiﬁed by densitometry scanning using the
Fusion imaging system and Bio-1D software (Peqlab).
2.4. Global lipidomics analysis of adipocytes
Extraction of 3T3-L1 adipocyte lipids was performed according to
the method described by Folch et al. [32]. The lipids were analysed by
liquid chromatography–mass spectrometry (LC–MS) using a Thermo
Orbitrap Exactive mass spectrometer (Thermo Scientiﬁc, Hemel
Hempstead, UK), equipped with a heated electrospray ionization
(HESI) probe and coupled to a Thermo Accela 1250 UHPLC system.All
samples were analysed in both positive and negative ion mode over
the mass to charge (m/z) range 200–2000. The samples were
injected on to a Thermo Hypersil Gold C18 column (2.1 mm  100
mm, 1.9 mm). Mobile phase A consisted of water containing 10 mM
ammonium formate and 0.1% (v/v) formic acid. Mobile phase B
consisted of 90:10 isopropanol/acetonitrile containing 10 mM
ammonium formate and 0.1% (v/v) formic acid. The initial
conditions for analysis were 65%A/35%B. The percentage of mobile
phase B was increased to 100% over 10 minutes and held for 7 min
before re-equilibration with the starting conditions for 4 min. All
solvents were LC–MS grade (Fisher Scientiﬁc, Loughborough, UK).
The raw LC–MS data were processed with Progenesis CoMet
v2.0 software (Non-linear Dynamics, Newcastle, UK) and searched
against LIPID MAPS (www.lipidmaps.org) for identiﬁcation.
2.5. Animals
Male C57BL/6 mice were randomised by body weight at three
months of age and fed CHOW, HFD or FEN-HFD for 20 weeks.
Analysed tissues were collected during previously performed
experiments as described in [6], whereby FEN-HFD prevented
obesity and factors associated with insulin resistance. Perigonadal
white adipose tissue (PG-WAT) from ad libitum fed mice was
rapidly dissected, frozen in liquid nitrogen, and stored at 80 C.
Animal procedures were approved by the University of Aberdeen
Ethics Review Board and performed under license (PPL60/3951)
approved by the UK Home Ofﬁce.
2.6. Quantitative analysis of ceramides and dihydroceramides in
adipose tissue
Lipids were extracted from murine adipose tissue according
to the method of Bligh and Dyer [33]. The ceramides and
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extraction chromatography. C17:0 ceramide and
C12:0 dihydroceramide (Avanti Polar Lipids, Alabaster, AL, USA)
were included in the experimental system as internal standardsFig. 1. FEN cannot inhibit PPARg agonist mediated 3T3-L1 differentiation. (A) Lipid stain
C3H10T1/2 cells differentiated with indicated compounds. Data was normalised to Nono,Y
VEH by one-way ANOVA with Tukey post hoc test. (B) Lipid stained 3T3-L1 adipoc
representative of cell morphology in left panel. Right panel is quantiﬁcation of lipids, n 
expression analysis of adipogenic (C) and retinoid (D) markers, n = 3. Signiﬁcance *P < (ISTD). LC–MS/MS analyses were performed in positive ion mode
on a Thermo TSQ Quantum Ultra triple quadrupole mass
spectrometer equipped with a HESI probe and coupled to a
Thermo Accela 1250 UHPLC system. The ceramides anded images at 200 magniﬁcation and expression analysis of adipogenic markers of
whaz and 18S, n = 4 biological replicates. Signiﬁcance *P < 0.05 vs -VE or #P < 0.05 vs
ytes, differentiated with indicated compounds. Middle panels are 200 images
= 5. Signiﬁcance *P < 0.001 vs VEH, #P < 0.001 vs ROSI and +P < 0.001 vs FEN. Gene
0.05 vs VEH or #P < 0.05 vs ROSI.
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(100  2.1 mm) (Phenomenex, Macclesﬁeld, UK). Mobile phase A
consisted of 90% H2O, 10% acetonitrile with 0.1% formic acid and
mobile phase B consisted of acetonitrile with 0.1% formic acid. The
gradient was held at 80% B for 1 min initially, increased to 100% B at
15 min, held at 100% B for 1 min and then re-equilibrated to
starting conditions with a total run time of 20 min. The ﬂow rate
was 500 ml/min with a column temperature of 40 C. All solvents
were HPLC grade or above (Fisher Scientiﬁc, Loughborough, UK).
The data were acquired and processed using Xcalibur software v2.1
(Thermo Scientiﬁc). The concentration of the ceramide and
dihydroceramide molecular species was determined by compari-
son to calibration curves generated with C16:0 and
C24:1 standards (Avanti Polar Lipids, Alabaster, AL, USA). Total
ceramide and dihydroceramide concentrations were calculated
from the summed concentrations of all the monitored molecular
species. All values were normalised to wet weight of PG-WAT.
2.7. Metabolomic proﬁling of adipose tissue
Metabolomic proﬁling was carried out on a ZICpHILIC column
(150  4.6 mm, 5 mm, HiChrom, Reading, UK) and an Orbitrap
Exactive MS using conditions described previously [34]. Data
extraction and data base searching were also carried out as
described previously [34].A
B
Fig. 2. Time and dose-dependent alterations in gene expression between FEN and RA tre
cells after 12 and 24 h of exposure to MDI and indicated compounds. Data was normalise
#P < 0.05 vs ROSI. Expression analysis of retinoid (B) and adipogenic (C) markers in 3T3-
was normalised to Nono, Ywhaz and 18S, n = 3 biological replicates. Signiﬁcance *P < 0.02.8. Statistics
Data represents the mean  SD and n indicates the number of
biological replicates. Data were analysed using one-way ANOVA
with Tukey’s multiple-comparison post-hoc test (or unpaired
Student’s t-test where stated) with P < 0.05 considered signiﬁcant.
3. Results
3.1. PPARg agonist driven adipocyte differentiation is inhibited by RA
but not FEN
FEN completely inhibited adipocyte differentiation in the 3T3-
L1 cell line [6] and in C3H10T1/2 pluripotent stem cells indicating
that inhibition of adipogenesis is a common characteristic of FEN
treatment (Fig. 1a). We examined whether FEN could inhibit
adipogenesis in 3T3-L1 cells stimulated with ROSI. RA was able to
completely inhibit differentiation (Fig. 1b) with ROSI present
(RA + ROSI). FEN was not able to inhibit adipogenesis in the
presence of ROSI, but decreased lipid accumulation when
compared to VEH or ROSI treatments (Fig. 1b). Moreover, RA + ROSI
was able to suppress levels of C/ebp alpha but FEN + ROSI was
unable to replicate this suppression (Fig. 1c). FEN + ROSI could not
suppress C/EBPa-PPARg target genes, Fabp4, Adiponectin (Fig. 1c)
and Fabp5 (not shown). While RA treatment inhibited adipogenesisC
atment. (A) Gene expression analysis of retinoid and adipogenic markers in 3T3-L1
d Nono, Ywhaz and Hprt, n = 3 biological replicates. Signiﬁcance *P < 0.05 vs VEH or
L1 adipocytes differentiated for 48 hours with MDI and indicated compounds. Data
5 vs VEH or #P < 0.05 vs RA (at equivalent dose).
Fig. 4. FEN decreases lipid accumulation in mature 3T3-L1 adipocytes independently of RARa signalling. (A) Lipid stained 3T3-L1 adipocytes, differentiated for 16 days with
indicated compounds added at day 8. Right panels are 200 images of cell morphology from left panels. (B) Lipid quantiﬁcation of cultures shown in A, n = 6. Signiﬁcance
*P < 0.001 vs VEH and #P < 0.01 vs VEH + ER. (C) Basal lipolysis by quantiﬁcation of glycerol in the culture media from indicated treatments. 3T3-L1 adipocytes were treated as
in (A), n = 7. Signiﬁcance +P < 0.001 vs -VE and *P < 0.001 vs VEH.
Fig. 3. RARa antagonism blocks inhibition of adipogenesis by FEN. (A) Lipid stained 3T3-L1 adipocytes, differentiated with indicated compounds +/ ER50891 (ER). Middle
panels are 200 images of cell morphology in left panel. Right panel indicates quantiﬁcation of lipids, n = 6. Signiﬁcance *P < 0.0001 vs FEN and #P < 0.0001 vs RA by t-test.
Gene expression analysis of adipogenic (B) and retinoid (C) markers. Signiﬁcance *P < 0.05 vs FEN and #P < 0.05 vs RA by t-test, n = 3.
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alpha induction, gene expression of terminal markers of adipo-
genesis (Fabp4 and Adiponectin) appeared unaffected in contrast to
treatment with RA alone. These ﬁndings highlight that several
markers should be used to draw conclusions when assessing
adipocyte differentiation.
RA + ROSI induced retinoid homeostasis genes Crbp1, Raldh1
and Rar gamma, although the increases in expression were partially
suppressed by ROSI (Fig. 1d). FEN + ROSI did not induce these
retinoid genes. These results suggest that induction of RA-
responsive genes is required for retinoid-mediated inhibition of
adipogenesis since PPARg stimulation can block this inhibition.
3.2. RARa antagonism leads to loss of FEN effects on inhibition of
adipogenesis
To account for the differences between FEN and RA observed
during ROSI induced differentiation, we hypothesized that FEN
induced retinoid signalling is less potent compared to RA. To test
this, we measured retinoid-responsive gene expression following
FEN/RA treatment during the early stages of adipogenesis (Fig. 2a)
and in response to increasing concentrations (Fig. 2b and c). We
determined that FEN induced retinoid signalling is 2–3 times less
potent than RA. Therefore, next we tested this RAR-dependence by
blocking RAR ligand-mediated signalling with a selective RARa
antagonist (ER50891). ER50891 blocked RA-induced inhibition of
adipogenesis and allowed accumulation of lipid (Fig. 3a). Similarly,
ER50891 blocked FEN-induced inhibition of adipogenesis (Fig. 3a).
In addition, RARa antagonism prevented inhibition of adipocyteTable 1
Identiﬁcation of the major lipid species altered with Fenretinide treatment in matur
L1 adipocytes differentiated for 16 days. FEN and RA at 1 mM or equivalent DMSO as VEH a
way ANOVA, **P < 0.01 and ***P < 0.001.
Increased speciﬁcally with FEN (fold change) 
Lipid ID vs VEH P value vs RA P value 
Cer (34:0) 5.27 *** 
Cer (40:0) 8.63 *** 
Cer (42:0) 16.45 ***
SM (33:0) 70.01 *** 21.03 *** 
SM (34:0) 4.32 *** 3.93 *** 
PC (38:4) 2.50 ***
DG (34:0) 1.76 *** 
DG (36:3) 1.32 ** 
DG (38:3) 4.30 *** 
DG (O-34:1) 3.23 *** 2.44 ***
TG (48:4) 32.25 *** 46.10 *** 
TG (56:4) 1.31 ** 
TG (38:1) 10.79 *** 3.94 
TG (39:1) 6.62 *** 2.90 
Key: Cer = ceramide; SM = sphingomyelin; PE = phosphatidylethanolamine; PC = phosphagenes (Fig. 3b) and inhibited Crbp1 and Raldh1 by 50% (Fig. 3c).
Overall, these ﬁndings strongly demonstrate that the mechanism
of FEN action to inhibit 3T3-L1 adipogenesis is mediated by ligand-
induced activation of RARa signalling and genes involved in
retinoid metabolism.
3.3. FEN acts through RAR-independent mechanisms to decrease lipid
levels in mature adipocytes
Next, we examined whether RAR-dependent pathways were
responsible for the FEN-induced decrease in lipid accumulation in
mature 3T3-L1 adipocytes [6]. Antagonism of RARa with
ER50891 failed to prevent this effect of FEN (Fig. 4a and b).
Moreover, FEN did not affect media glycerol levels when compared
to VEH controls suggesting that the basal rate of lipolysis is not
altered by FEN (Fig. 4c). ROSI increased media glycerol levels
indicating a putative increase in lipolysis consistent with an
increase in ATGL expression [6,35,36]. These data suggest that the
FEN-induced decrease in lipid accumulation in mature 3T3-L1
adipocytes is via an RAR-independent mechanism(s).
3.4. Lipidomics analysis of FEN treated 3T3-L1 adipocyte cells
Previous studies have identiﬁed alterations in ceramide
biosynthesis and autophagy induction associated with FEN
treatment [19,37], however it is unknown if FEN can alter these
pathways in adipocytes. We performed global lipidomics analysis
in mature adipocytes to determine whether ceramide lipid
species (i.e. sphingolipids) were altered. FEN speciﬁcally led to ae 3T3-L1 adipocytes. LC–MS analysis was performed on lipid extracts from 3T3-
dded at day 8, n = 7 for VEH, n = 8 for FEN and RA. Signiﬁcance was calculated by one-
Decreased speciﬁcally with FEN (fold change)
Lipid ID vs VEH P value vs RA P value
SM (34:1) 2.23 ***
SM (42:3) 2.19 ***
PE (34:0) 2.21 ***
PE (34:1) 3.64 ***
PE (36:1) 2.57 ***
PE (36:2) 4.47 ***
PC (32:1) 4.02 *** 4.14 ***
PC (32:2) 6.66 *** 8.50 ***
PC (34:1) 1.97 ***
PC (34:2) 2.78 ***
TG (36:0) 6.71 *** 2.74 ***
TG (37:0) 8.87 *** 3.28 ***
TG (38:0) 6.12 ***
***
***
TG (40:0) 4.82 ***
TG (40:1) 7.76 *** 2.50 ***
TG (40:2) 9.53 *** 3.48 ***
TG (42:2) 4.97 *** 2.16 ***
TG (44:0) 1.93 ***
TG (44:2) 3.00 ***
TG (45:2) 2.44 ***
TG (46:2) 2.73 ***
TG (46:3) 3.42 *** 2.08 ***
TG (47:3) 3.09 ***
TG (48:2) 1.50 ***
TG (49:2) 2.12 ***
TG (50:4) 2.73 ***
TG (51:3) 5.44 *** 3.04 ***
TG (53:3) 1.82 ***
tidylcholine; PS = phosphatidylserine; TG = triglyceride; DG = diglyceride.
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compared to VEH and a 5-fold increase in dihydroceramide (Cer
34:0) compared to RA (Table 1). FEN also increased dihydrocer-
amide-containing sphingomyelin (SM 33:0 and 34:0) compared to
RA or VEH. FEN treatment led to a reciprocal decrease in ceramide-
containing sphingomyelin (SM 42:3 and 34:1) compared to VEH
and RA, respectively (Table 1).
Interestingly, both FEN and RA exposure resulted in a complex
remodelling of triacylglyceride species, with similar increases
(from 2- to 18-fold) in longer chain and desaturated fatty acids
(Table 2). FEN and/or RA also decreased a number of triacylgly-
ceride species (Tables 1 and 2). However, FEN decreased many
more triacylglyceride lipid species (from 2 to 11-fold) and by a
greater amount compared to RA. These ﬁndings are in agreement
with a FEN-speciﬁc (RAR-independent mechanism) to decrease
lipid accumulation in mature adipocytes (Fig. 4 and Ref. [6]).
3.5. FEN increases adipose dihydroceramide levels in vivo
To translate our 3T3-L1 adipocyte ﬁndings to an in vivo setting,
we quantiﬁed ceramide and dihydroceramide lipid species fromTable 2
Identiﬁcation of the major lipid species increased or decreased by both FEN and RA
or speciﬁcally RA treatment in mature 3T3-L1 adipocytes. LC–MS analysis was
performed on lipid extracts from 3T3-L1 adipocytes differentiated for 16 days. FEN
and RA at 1 mM or equivalent DMSO as VEH added at day 8, n = 7 for VEH, n = 8 for
FEN and RA. Signiﬁcance was calculated by one-way ANOVA, **P < 0.01 and
***P < 0.001.
Increased by both FEN and RA (fold change vs VEH)
Lipid ID FEN P value RA P value
PC (44:3) 9.54 *** 7.59 ***
PS (44:1) 4.00 *** 3.45 ***
PS (44:2) 6.20 *** 5.03 ***
TG (56:6) 2.33 *** 2.55 ***
TG (56:7) 3.11 *** 3.87 ***
TG (57:4) 3.18 *** 2.98 ***
TG (57:5) 14.12 *** 12.18 ***
TG (57:6) 17.74 *** 17.76 ***
TG (58:7) 11.00 *** 14.39 ***
Increased speciﬁcally by RA (fold change vs VEH)
Lipid ID FEN P value RA P value
PS (44:3) 2.51 ***
Decreased by both FEN and RA (fold change vs VEH)
Lipid ID FEN P value RA P value
TG (38:1) 10.79 *** 2.74 ***
TG (40:1) 7.76 *** 3.10 ***
TG (44:1) 2.85 *** 2.09 ***
TG (45:1) 2.41 *** 1.88 ***
TG (46:1) 2.51 *** 1.95 ***
TG (47:1) 2.05 *** 1.75 ***
TG (48:1) 2.22 *** 1.86 ***
TG (48:2) 3.08 *** 1.76 ***
TG (48:5) 2.73 *** 1.66 ***
TG (49:1) 1.62 *** 1.58 ***
TG (50:1) 1.43 *** 1.60 ***
TG (50:2) 1.95 *** 1.46 ***
TG (51:2) 2.97 *** 1.68 ***
Decreased speciﬁcally by RA (fold change vs VEH)
Lipid ID FEN P value RA P value
TG (46:0) 1.60 ***
TG (47:0) 1.39 ***
TG (48:0) 1.40 **
TG (49:0) 1.39 ***
TG (52:1) 1.35 ***PG-WAT of mice fed HFD +/ FEN or normal CHOW for 20 weeks
[6]. FEN-HFD prevented obesity, hyperglycemia, insulin resistance
and hepatic steatosis in these mice [6]. HFD increased adipose
ceramide C18:1 and C18:0 compared to CHOW (Fig. 5a). FEN-HFD
completely prevented this elevation. HFD and FEN-HFD both
decreased other ceramide species (C22:1, C24:1 and C24:0).
Strikingly, FEN-HFD increased almost all dihydroceramides and
the ratio of dihydroceramide:ceramide in PG-WAT of treated mice
(Fig. 5b and c). Moreover, FEN increased total tissue dihydrocer-
amide levels by 7-fold (Fig. 5d). Enzymes involved in ceramide
biosynthesis, dihydroceramide desaturase, (Des1) and ceramide
synthase (CerS)-6 have been recently implicated with increased
enhanced ceramide production mediating high-fat diet induced
metabolic dysregulation in adipose tissue of mice and humans
[38–40]. HFD increased WAT Des1 gene expression compared to
CHOW (Fig. 5e). FEN-HFD completely prevented this elevation;
moreover, FEN-HFD decreased CerS6 gene expression compared to
HFD. Therefore, inhibiting adipose ceramide synthesis may
contribute to the beneﬁcial effects with respect to adiposity and
adipocyte insulin sensitivity previously observed with FEN
treatment in mice [6,16].
3.6. FEN completely normalises HFD induced impairments to
mitochondrial function in vivo
Since excess ceramide synthesis has been negatively associated
with mitochondrial function and insulin sensitivity, we performed
global metabolomics analysis of PG-WAT from mice fed HFD +/
FEN treatment. HFD led to an accumulation of numerous
acylcarnitines, indicative of impaired b-oxidation (Table 3). FEN
completely normalised all of these elevations to levels measured in
CHOW-fed mice (Table 3). FEN also completely prevented the rise
in tricarboxylic acid (TCA)-cycle intermediates and oxidative stress
markers (Table 3). This strongly suggests that FEN-treatment in
vivo can alleviate disturbances to adipose tissue mitochondrial
function resulting from HFD feeding.
3.7. FEN can induce markers of cellular stress and autophagy in
mature adipocytes
To determine whether FEN’s inhibition of ceramide biosynthe-
sis was associated with the induction of cellular stress and survival
responses as reported in cancer cell lines, we examined the levels
of phospho-eIF2a, phospho-p38 and markers of autophagy. FEN
increased levels of phospho-eIF2a (downstream of the PERK stress
response pathway) and phospho-p38 (a mitogen activated protein
kinase) (Fig. 6a). FEN also increased protein expression of
Beclin1 and LC3B II which are required for autophagosome
formation (Fig. 6a). FEN did not increase the expression of Atf4,
the spliced isoform of Xbp1 or Chop. Surprisingly, FEN decreased
gene expression levels of Atf4 and Chop, which may indicate the
induction of pro-survival pathways rather than progression to
apoptosis in 3T3-L1 cells (Fig. 6b).
3.8. FEN metabolite 4-OXO cannot inhibit 3T3-L1 adipogenesis
FEN can activate both RAR-dependent and -independent
signalling pathways in 3T3-L1 cells. Previous studies have
determined that 4-oxo-N-(4-hydroxyphenyl)retinamide, an oxi-
dised FEN catabolite hereafter termed 4-OXO [41], operates in a
RAR-independent manner, can manipulate ceramide biosynthesis
similarly to FEN and is more potent than the parent compound
[42,43]. We tested whether 4-OXO was responsible for the
inhibition of adipogenesis and/or decreased lipid accumulation
in 3T3-L1 cells. 4-OXO was unable to inhibit adipogenesis in 3T3-L1
cells, however, lipid accumulation was less than in VEH treated
Fig. 5. FEN increases dihydroceramide levels in adipose tissue. Quantiﬁcation of ceramide (A) or dihydroceramide species (B) in PG-WAT from mice fed CHOW, HFD or FEN-
HFD. (C) The relative fold change in dihydroceramide to ceramide. (D) Total levels of ceramide, dihydroceramide and the dihydroceramide/ceramide ratio. Signiﬁcance
*P < 0.05 vs CHOW and #P < 0.05 vs HFD. n = 5 for CHOW, n = 6 for HFD and FEN-HFD. (E) Gene expression analysis of WAT from mice fed CHOW (n = 6), HFD (n = 6) or FEN-HFD
(n = 8). Data was normalised to Gapdh. Signiﬁcance *P < 0.05 vs CHOW and #P < 0.05 vs HFD (by t-test for Cers6).
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up to 10 mM were well tolerated (data not shown). Unexpectedly,
4-OXO resulted in increased expression levels of adipogenic
markers (Fig. 7b). Retinoid genes were down regulated by
differentiation and 4-OXO was unable to induce any of these
genes above the levels observed in VEH (Fig. 7c). Thus, the
catabolism of FEN to 4-OXO does not contribute to the inhibition of
3T3-L1 differentiation, however it appears 4-OXO may have non-
retinoid, insulin-sensitizing properties. To test this further, insulin
stimulated phosphorylation of Akt (phospho-Akt) was examined.
VEH treated cultures responded poorly to insulin stimulation with
only small increases in phospho-Akt levels observed when
compared to saline controls (Fig. 7d). This is likely to be a result
of the development of insulin resistance through chronic insulin
treatment, which has been described previously [44]. 4-OXO
increased phospho-Akt levels by almost 3-fold compared to VEH
controls in the absence of insulin. 4-OXO further increased
phospho-Akt levels with insulin stimulation indicating that
treatment with 4-OXO results in increased insulin signalling in
differentiated 3T3-L1 adipocytes (Fig. 7d).Next we investigated whether 4-OXO exhibited other RA-
independent signalling properties as observed with FEN treat-
ment. 4-OXO led to increased levels of phospho-p38, phospho-
eIF2 a and LC3B II indicating the induction of cellular stress
responses and autophagy induction (Fig. 8). Thus, the RA-
independent effects of FEN treatment are also exhibited by
4-OXO in 3T3-L1 adipocytes.
4. Discussion
The data presented here demonstrates that FEN can increase
dihydroceramide and dihydrosphingomyelin lipid species inde-
pendently of RAR-signalling, which is associated with activation of
cellular stress responses and decreased lipid content in mature
3T3-L1 adipocytes. Moreover, our translational ﬁndings from
mouse adipose tissue suggest that the manipulation of ceramide
biosynthesis is also linked to normalisation of mitochondrial
function in association with FEN-mediated inhibition of HFD-
induced obesity and insulin resistance. This is in contrast to the
mechanism of FEN action to inhibit 3T3-L1 differentiation, which
Table 3
Metabolomics analysis of PG-WAT from HFD mice treated with FEN. Levels of carnitine, TCA cycle intermediates and oxidative stress markers in PG-WAT following global
metabolite analysis by LC–MS. For each group n = 5 mice. All data represents mean and signiﬁcance **P < 0.01 and ***P < 0.001 vs CHOW by one-way ANOVA with Tukey post
hoc test.
m/z Retention time Compound Acyl chain Relative to CHOW
HFD FEN-HFD
Carnitines
162.113 12.9 (S)-Carnitine 0.40*** 0.53***
248.149 11.0 Hydroxybutyrylcarnitine C4:0 2.91** 0.85
276.180 8.8 Hydroxyhexanoylcarnitine OH–C6:0 3.86** 1.21
342.264 4.6 trans-2-Dodecenoylcarnitine C12:1 2.89** 1.08
344.279 4.6 Dodecanoylcarnitine C12:0 3.18** 0.88
360.275 4.6 2-Hydroxylauroylcarnitine OH–C12 8.77** 2.03
370.295 4.6 trans-2-Tetradecenoylcarnitine C14:1 3.14** 1.19
372.311 4.5 Tetradecanoylcarnitine C14:0 3.68*** 1.08
386.290 4.6 3-Hydroxy-cis-5-tetradecenoylcarnitine OH–C14:1 11.52** 2.56
388.306 4.6 2-Hydroxymyristoylcarnitine OH–C14:0 12.56** 1.91
398.327 4.5 9-Hexadecenoylcarnitine C16:1 3.95** 1.01
400.342 4.4 [FA] O-Palmitoyl-R-carnitine C16:0 5.31** 1.21
414.322 4.6 3-Hydroxy-9-hexadecenoylcarnitine OH–C16:1 13.93** 4.16
416.337 4.6 2-Hydroxyhexadecanoylcarnitine OH–C16:0 18.07*** 2.53
426.358 4.3 11Z-Octadecenylcarnitine C18:1 8.55** 1.69
442.353 4.5 3-Hydroxy-9Z-octadecenoylcarnitine OH–C18:1 22.25*** 3.26
TCA intermediates
173.010 17.5 Aconitate 1.83*** 1.02
147.030 13.1 2-Hydroxyglutaric acid 2.30** 0.8
145.014 14.9 Ketoglutaric acid 6.07** 0.80
133.015 15.4 Malic acid 1.80*** 0.94
115.004 15.4 Fumaric acid 1.87*** 0.95
117.019 14.5 Succinic acid 1.48** 0.86
191.020 17.7 Citrate 2.73** 0.89
Oxidative stress
308.091 13.5 Glutathione 2.05** 0.88
613.160 16.9 GSSG 1.60 0.78
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RARa signalling and induction of genes involved in retinoid
metabolism (summarised in the graphical abstract).
Whereas RA was able to completely inhibit adipogenesis in the
presence of ROSI, FEN was only able to partially prevent lipidFig. 6. FEN induces markers of cellular stress and autophagy in 3T3-L1 adipocytes. (A
differentiated for 16 days with indicated compounds added from day 8. Right panels a
PTP2 levels, n = 4. Signiﬁcance *P < 0.01 vs VEH and #P < 0.05 vs RA. (B) Gene expression
VEH, n = 3.accumulation. ROSI can stimulate adipogenesis via increased
PPARg occupancy at nearby target genes but can also repress some
genes that appear to be more dependent on C/EBPa [45]. Our
results suggest that the ROSI-induced down-regulation of retinoid
homeostasis genes can be overcome by RA via co-ordinate) Western blot analysis of ER stress and autophagy markers in 3T3-L1 adipocytes
re quantiﬁcation of western blots in left panels. Proteins were normalised to SH-
 analysis of ER stress markers at day 16 of differentiation. Signiﬁcance *P < 0.01 vs
Fig. 7. FEN catabolite 4-OXO does not inhibit 3T3-L1 adipogenesis. (A) Lipid stained 3T3-L1 adipocytes differentiated with indicated compounds. Bottom left panels are 200
images of cell morphology from upper left panel. Right panel is quantiﬁcation of lipids. Signiﬁcance *P < 0.001 vs -VE and #P < 0.001 vs VEH, n = 4. Gene expression analysis of
adipogenic (B) or retinoid markers (C). Signiﬁcance *P < 0.01 vs -VE and #P < 0.05 vs VEH. Expression data was normalised to Nono, Ywhaz and 18S, n = 4. (D) Western blot
analysis of p-AKT S473 in differentiated adipocytes. Cells were serum starved for 16hr and treated with 20 nM insulin (+) or saline () for 15 min. Right panel is quantiﬁcation
of western blots. Proteins were normalised to total AKT levels, n = 3. Signiﬁcance *P < 0.001 vs VEH () and #P < 0.01 vs 4-OXO ().
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genes such as Crbp1 and Rar gamma. Under these conditions, the
less potent FEN could not repress C/EBPa or induce retinoid
responsive genes and thus could not prevent adipogenesis.
Although liganded RAR has been known to inhibit adipogenesis
through the prevention of C/EBPb mediated transcription, recent
studies have also pointed to an inhibitory role for CRBP1 in
adipogenesis and triacylglyceride accumulation [3].Fig. 8. 4-OXO induces cellular stress and autophagy markers. Western blot analysis of E
compounds. Right panels are quantiﬁcation of western blots in left panels. Proteins were nThe ability of FEN treatment to decrease adipocyte lipid content
in mature adipocytes was found to be RARa independent,
consistent with previous reports that RA is unable to replicate
this effect [6,27,28]. Moreover, dihydroceramide lipid species
increased speciﬁcally in FEN-treated adipocytes, similarly to
reported effects in carcinoma cells [37,46]. This effect appears to
occur via direct inhibition of Des1 activity and mRNA, which
catalyses the ﬁnal step in de novo ceramide synthesis [43].R stress and autophagy markers in 3T3-L1 adipocytes differentiated with indicated
ormalised to total p38 or eIF2a levels, n = 6. Signiﬁcance *P < 0.001 vs VEH by t-test.
96 G.D. Mcilroy et al. / Biochemical Pharmacology 100 (2016) 86–97However, this is the ﬁrst report that FEN can cause such alterations
or in addition, inhibit Cers6 gene expression in adipocytes or
adipose tissue. Thus, the complete normalisation of impaired
mitochondrial b-oxidation and TCA cycle ﬂux in adipose tissue
suggests that in vivo, FEN may inhibit obesity and insulin resistance
via inhibition of ceramide-induced insulin resistance and attenua-
tion of mitochondrial dysfunction.
Accumulation of numerous acylcarnitines and ceramide linked
to excess lipid supply and impaired mitochondrial fatty acid
b-oxidation in skeletal muscle is associated with muscle insulin
resistance [47,48]. Moreover, S. Summers and co-workers have
shown FEN to directly prevent lipid induced insulin resistance in
cultured myotubes and isolated muscles strips in association with
increases in dihydroceramide levels [18]. However, insulin
sensitization after treatment with the thiazolidinedione class of
PPARg agonists is associated with increased adipose mitochondrial
capacity and expression of adipose genes essential for branched-
chain amino-acid oxidation, fatty acid b-oxidation, TCA-cycle and
oxidative phosphorylation pathways [49,50]. Thus overall, FEN
appears to correct these impairments in lipid homeostasis
pathways in multiple insulin sensitive tissues in vivo [51–54].
The FEN metabolite 4-OXO [41] has been identiﬁed as
biologically active and inhibits Des1 more potently than FEN
[43]. Thus, 4-OXO may be partly responsible for some of the effects
observed in response to FEN treatment [42]. We have revealed that
4-OXO is poor at inducing RAR-signaling and thus unable to inhibit
3T3-L1 adipogenesis. However, 4-OXO increased adipogenic
biomarkers and insulin sensitivity. Thus, elevated p-AKT levels
are probably due to the non-RAR signaling characteristics of
FEN and FEN-like compounds, such as inhibition of ceramide
synthesis [37,43]. These ﬁndings identify that 4-OXO may be a
novel and previously unexplored therapeutic candidate to improve
adipocyte insulin sensitivity without negatively impacting upon
adipocyte differentiation or other non-beneﬁcial effects of retinoid
treatment.
We found that both FEN and 4-OXO, (but not RA), led to
increases in markers of cellular stress and autophagy without
inducing apoptotic cell death. Increased dihydroceramide species
presents a potential non-RAR mechanism of FEN/4-OXO action
linked to modulation of nutrient stress pathways. Regulation of
these pathways has been shown to be impaired and contribute to
the pathogenesis of diabetes [22,23]. Induction of ER stress and
autophagy has been observed in variety of different cells types
after FEN or dihydroceramide supplementation [19–21] and may
account for the decrease in adipocyte lipid content in mature 3T3-
L1 adipocytes. A recent study indicated that hypertrophic
adipocytes fail to process autophagasomes through reduced
autophagic ﬂux [55]. This suggests defective autophagy may be
associated with or even responsible for increases in adiposity and
states of obesity. FEN and 4-OXO may increase autophagic ﬂux and
alleviate cellular disturbances that arise in hypertrophic adipo-
cytes as a result of diet-induced obesity. However, further
investigations will be required to determine the importance of
this ﬁnding in vivo.
Overall, our ﬁndings indicate that FEN appears to display the
unique ability to inhibit adipocyte differentiation and hypertrophy
in vitro and these effects are mediated through distinct mechanis-
tic pathways that are translated in vivo. We have conﬁrmed that
like RA, FEN inhibits adipocyte differentiation in vitro through
RARa-dependent signaling. However, the non-RAR effects of FEN
and its catabolite 4-OXO to modulate ceramide synthesis appear to
be linked to improved mitochondrial function and modulation of
cellular stress responses and autophagy. Future experiments will
be required to demonstrate a causal molecular link between the
alterations in ceramide synthesis and the observed metabolic
outcomes. Our ﬁndings suggest that this unique combination ofbiological effects may be responsible for the low toxicity and
beneﬁcial effects of FEN treatment to inhibit obesity and insulin
resistance.
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